A

Amplia Therapeutics
ATX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
A$91.57M
EV
A$80.72M
Shares Outstanding
430.64M
Beta
0.69

Wall Street View

Analyst Rating
NO_OPINION
Analyst Target Price
A$0.24
P/E 2026E
-
P/Revenue 2026E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Amplia Therapeutics Limited

gainify

A

Amplia Therapeutics Limited

ATX

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in ph...

Sector

Healthcare

Industry

Biotechnology

CEO

Burns, Christopher

Employees

IPO Date

2014-01-12

Headquarters

350 Queen Street, Level 17, Melbourne, Victoria, 3000, Australia

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.